Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine

Publication date: 5 January 2017
Source:Vaccine, Volume 35, Issue 2
Author(s): Elizabeth A. Poore, Dawn K. Slifka, Hans-Peter Raué, Archana Thomas, Erika Hammarlund, Benjamin K. Quintel, Lindsay L. Torrey, Ariel M. Slifka, Justin M. Richner, Melissa E. Dubois, Lawrence P. Johnson, Michael S. Diamond, Mark K. Slifka, Ian J. Amanna
West Nile virus (WNV) is a mosquito-transmitted pathogen with a wide geographical range that can lead to long-term disability and death in some cases. Despite the public health risk posed by WNV, including an estimated 3 million infections in the United States alone, no vaccine is available for use in humans. Here, we present a scaled manufacturing approach for production of a hydrogen peroxide-inactivated whole virion WNV vaccine, termed HydroVax-001WNV. Vaccination resulted in robust virus-specific neutralizing antibody responses and protection against WNV-associated mortality in mice or viremia in rhesus macaques (RM). A GLP-compliant toxicology study performed in rats demonstrated an excellent safety profile with clinical findings limited to minor and transient irritation at the injection site. An in vitro relative potency (IVRP) assay was developed and shown to correlate with in vivo responses following forced degradation studies. Long-term in vivo potency comparisons between the intended storage condition (2–8°C) and a thermally stressed condition (40±2°C) demonstrated no loss in vaccine efficacy or protective immunity over a 6-month span of time. Together, the positive pre-clinical findings regarding immunogenicity, safety, and stability indicate that HydroVax-001WNV is a promising vaccine candidate.



http://ift.tt/2hoTrqM